Tools
Change country:

A few idealistic Canadians are trying to replant the world’s forests with flying machines

The battle against climate change can be waged with sober policymaking, an engaged citizenry and corporate responsibility. It also, it turns out, can be fought by a few hipster Millennials with flying machines.
Read full article on: washingtonpost.com
Cyber Monday deals 2021: Live updates on the best sales and products
One of the most sought-after shopping deals events is finally here. Hello Cyber Monday, home of Internet-housed amazing savings that you can shop from the comfort of your home. From incredible Cyber Monday deals to unbeatable discounts on Amazon devices, the hottest smart TVs and home gym-ready exercise equipment, you’ll want to have this tab...
4 m
nypost.com
Omicron May Fuel Surges, WHO Warns Amid Transmission Concern
The Geneva-based WHO assessed the variant’s risk as “extremely high” and called on member states to test widely.
5 m
time.com
Mayors, Borough Bosses and Land Commissioners: Why Donald Trump Is Making Extremely Local Endorsements
During their local mayoral race in early November, town residents in Hialeah, Florida, population 230,000, heard a familiar voice in a campaign ad for the city’s election. “Steve Bovo,” boomed former President Donald Trump’s voice, in an ad spliced with video of Trump name checking the Republican candidate during a rally in 2020. Boosting Bovo’s…
6 m
time.com
Live betting is the wave of the future, but not for the faint of heart
Live betting gives viewers something to do while following along, but it can be extremely dangerous for the undisciplined.
6 m
nypost.com
Save on beauty and more with Saks Fifth Avenue Cyber Monday 2021 deals
Shop the best deals at Saks Fifth Avenue during its Cyber Monday 2021 sales on beauty, apparel and more.
6 m
nypost.com
This 33-year-old made the world's fastest electric car. Now he's running Bugatti
At 17, Mate Rimac started his electric supercar company out of his garage. Now he's tasked with bringing his visionary thinking to one of the most legendary brands in history.
7 m
edition.cnn.com
Lebanese protesters block roads over economic meltdown
Demonstrators, some of them burning tyres, blocked roads across parts of Lebanon on Monday in protest at the country's economic meltdown, days after the Lebanese pound sank to new lows.
9 m
edition.cnn.com
Penguins send letters to Santa at London zoo
These penguins dropped their Christmas lists into a mailbox marked for the North Pole. Watch the adorable animal video filmed at the ZSL London Zoo. “We’re pretty sure Santa now knows to get something fishy for the penguins this year,” zookeeper Jessica Jones quipped.
nypost.com
Menorah lightings mark start of Hannukah
The National Hannukah Menorah was lit outside the White House on Sunday night, and a 36-foot tall Menorah was lit in New York as Jews around the world celebrated the first night of Hannukah. (Nov. 29)      
usatoday.com
Trial set to start on charges Smollett faked racist attack
Jussie Smollett, a Black and openly gay actor, reported to Chicago police that he was the victim of a hate crime. Nearly three years later, Smollett is about to stand trial on charges that he staged the whole thing.
foxnews.com
Macao casino shares tumble after police arrest Suncity founder
Macao casino stocks slid on Monday, rattled by the arrests of 11 people over alleged links to cross-border gambling and money laundering, with the founder of the gaming hub's biggest junket operator among those detained.
edition.cnn.com
The IOC’s Treatment of Missing Chinese Tennis Star Peng Shuai Is Disturbingly On-Brand
Photo Illustration by Thomas Levinson/The Daily Beast/GettyLast week, Human Rights Watch addressed a public letter to the International Olympic Committee, a kleptocracy that owns and operates the Summer and Winter Olympic Games, calling on the IOC to stop promoting “Chinese state propaganda” regarding tennis star Peng Shuai’s sexual-assault allegations against former People’s Republic of China Vice Premier Zhang Gaoli, and subsequent disappearance.“The IOC has vaulted itself from silence about Beijing’s abysmal human rights record to active collaboration with Chinese authorities in undermining freedom of speech and disregarding alleged sexual assault,” read the letter, quoting Yaqiu Wang, a policy researcher at Human Rights Watch. “The IOC appears to prize its relationship with a major human rights violator over the rights and safety of Olympic athletes.”There’s something bitterly funny about HRW shaming the IOC for promoting authoritarianism, because even a cursory reading of the history of the IOC is crystal clear on the matter: the IOC loves enabling authoritarianism. Can’t get enough of it. Telling the IOC to stop collaborating with violent, autocratic forces is like telling your dog to stop eating cat poop from the litter box. Sure, they might look at you with sad ol’ eyes for a second, but they’re just jonesing for another bite of that precious, delicious dung.Read more at The Daily Beast.
thedailybeast.com
Why Joe Biden Should Want Donald Trump to Run Again
While Democrats might despise the former president, his presence in a race could provide a clearer route to take tactically.
newsweek.com
Coronavirus variants: Here's what we know
Omicron, the newest coronavirus variant, is also the quickest to be labeled a "variant of concern" by the World Health Organization because of its seemingly fast spread in South Africa and its many troubling mutations.
edition.cnn.com
Omicron COVID Variant Symptoms Compared to Delta, Other Forms of the Virus
The South African doctor who first reported the Omicron variant says she noticed two common symptoms were missing from patients with this form of coronavirus.
newsweek.com
Sea Lion Caught by Police After Going for Wander Around Oregon City
The sea lion was spotted in Lincoln City after swimming up the river and making its way through a neighbourhood.
newsweek.com
No, the Ghislaine Maxwell Trial Does Not Have a Gag Order
Several social media posts have claimed that members of the press have been barred from accessing the courtroom.
newsweek.com
How Boeing Was Set on the Path to Disaster by the Cult of Jack Welch
JASON REDMONDOn April 20 this year, a group of the largest stakeholders in Boeing took part in a virtual version of the company’s annual general meeting. A few hours before the meeting opened online, they learned something that took them by surprise: The retirement age for the top job, CEO of the aerospace colossus, was suddenly being raised from 65 to 70.This meant that the current CEO, Dave Calhoun, who was 64, could enjoy at least another five years in the job. A move like that would normally indicate that the stakeholders were so pleased with the way a company was being run that they thought the best way of keeping it that way was to leave the boss in place rather than replace him.But this was Boeing, and the company had never been in worse shape. Calhoun had been in charge since January 2020. In that time, its previously stellar reputation for engineering excellence had been publicly shredded after two crashes of its newest jet, the 737MAX, had killed 346 people, because of serious failures in Boeing’s safety regimen. At the same time, other airplane programs, both commercial and military, were plagued with problems, and its effort to catch up with Elon Musk’s SpaceX program supplying astronaut-carrying capsules to NASA suffered repeated and ignominious failures.Read more at The Daily Beast.
thedailybeast.com
Alleged Epstein madame Ghislaine Maxwell on trial — here’s what to expect
Ghislaine Maxwell, the accused longtime madame of pedophile financier Jeffrey Epstein, will go on trial Monday -- beginning the final act of criminal proceedings.
nypost.com
Jussie Smollett's trial starts today. This is how we got here
Jury selection starts Monday in the trial of former "Empire" star Jussie Smollett, who is accused of making false reports to authorities that he was the victim of a racist and homophobic attack in 2019.
edition.cnn.com
Lauren Boebert Says Ghislaine Maxwell Trial Will Spur 'Misguided Outrage'
Ghislaine Maxwell is accused of grooming underage girls to have sex with convicted paedophile Jeffrey Epstein.
newsweek.com
NFL Week 13 best bets: Two games with intriguing early odds
Week 12 of the NFL season offered plenty of surprises, but will Week 13 offer more value for bettors? Here are two games worth your time and money.
latimes.com
Cardiac Angiosarcoma Symptoms Explained As Virgil Abloh, Off-White Founder, Dies
The influential fashion designer, 41—who was creative director for Louis Vuitton—had been receiving treatment for the cancer privately for more than two years.
newsweek.com
Stalled since June, Iran nuclear talks to resume
The US and its allies will restart Iran nuclear talks unsure how Tehran's new government will approach negotiations, not optimistic about the prospects ahead and emphasizing that if diplomacy fails, the US is "prepared to use other options." CNN's Nic Robertson reports.
edition.cnn.com
5 things to know for November 29: Coronavirus, Iran, Capitol riot, Taiwan, Arbery
Here's what else you need to know to Get Up to Speed and On with Your Day.
edition.cnn.com
From Waukesha to San Francisco | Opinion
The deadly actions of the last few days should serve as a wake-up call to most Americans.
newsweek.com
The New COVID Drugs Are a Bigger Deal Than People Realize
Although masks, distancing, ventilation, testing, and contact tracing have all helped forestall a collapse of the American health-care system under the weight of COVID-19, the pandemic will come under control in only two ways: Preventives—specifically vaccines—will harness people’s immune system to keep them from becoming infected, getting sick, and spreading the coronavirus, while targeted therapeutics will offer hope to those who have already developed symptoms. The emergence of Omicron, a worrisome new variant of the coronavirus, underscores the need to use multiple tools to fight the disease. In infectious diseases, control of a pathogen means reducing its impact even if it remains endemic in the world. Fortunately, the United States is poised to authorize two oral antivirals: molnupiravir and Paxlovid. The former is the generic name of a drug made by Merck; the latter is the trade name of a drug combination made by Pfizer. Both come in pill form, and a five-day treatment course of each will provide certain patients with significant benefits.These miraculous drugs arrived with minimal fanfare but represent the biggest advance yet in treating patients already infected with COVID-19. The supply of vaccines in the U.S. has exceeded demand for some time, and authorities recently widened eligibility to include children as young as 5, but uptake is not universal. Millions of Americans have decided, for a variety of reasons, not to get shots, while many more around the globe have yet to be offered a vaccine. And although the vaccines have remained amazingly effective against severe disease, some patients, especially those who are older or immunocompromised, remain at risk of hospitalization if they get a breakthrough infection. The widespread use of oral treatments for influenza hints at the value of COVID drugs that can be provided in an outpatient setting and reduce the severity of symptoms for unvaccinated and vaccinated patients alike.[Read: Timing is everything for Merck’s COVID pill]Molnupiravir and Paxlovid are particularly exciting because antivirals that effectively target viruses at specific points in their life cycle are the “holy grail” of viral therapeutics—as past experience with other viruses has shown. Infection with HIV was fatal for nearly all patients until antivirals were developed against enzymes crucial to viral replication and researchers figured out how to combine those drugs to maximize their effectiveness and limit the emergence of resistant viral strains. These changes revolutionized HIV treatment, massively improving the prognosis for people who had access to antivirals. Instead of developing severe illness, treated patients could live healthily and expect normal life spans.The development of these highly active oral antivirals for HIV infection took a decade and a half after the disease first came to light; the incredible progress in COVID-19 therapeutics took 18 months. Intriguingly, the COVID-19-treatment research borrowed many ideas from the HIV field; the two new COVID-19 drugs focus on similar pathways in the viral life cycle that HIV drugs target. In essence, these drugs prevent the target virus from reproducing itself. Because they work differently from the majority of COVID-19 vaccines, which teach the immune system to identify and attack the coronavirus’s characteristic spike protein, the antivirals remain effective against mutant variants whose spike proteins are harder for immune cells to recognize. Designing, manufacturing, and distributing vaccines updated for new variants will take time, so the availability of antivirals will be all the more essential.The rapid development of vaccines against COVID-19—something that doesn’t yet exist for HIV—has overshadowed the progress on treatments. And yet, the need and public demand for effective medications is evident. Doctors and patients have sought out potential oral COVID-19 treatments, including drugs such as hydroxychloroquine and ivermectin, that did not prove effective in clinical trials. But researchers needed to keep working on the question, because COVID-19 will be with us for the long haul. Although health experts agree that preventing a disease is better than treating its symptoms, not everyone will get vaccinated. People who become infected are worthy of compassion and care, regardless of the circumstances of their infection, and medical treatments that shorten the period of viral transmission and keep unvaccinated COVID-19 patients out of hospital beds will protect everyone.The COVID-19 treatments that have shown some effectiveness up to this point have significant drawbacks. Remdesivir is an intravenous antiviral used for hospitalized patients with COVID-19. But by the time a patient is admitted, the virus may already have caused considerable damage, and viral replication may have stopped. An intravenous drug has far less power to affect the trajectory of the pandemic than affordable, effective, and short courses of oral pills do. Until now, the only outpatient therapeutic for COVID-19 has been monoclonal antibody treatments, which are effective in preventing severe disease in high-risk patients. But they are expensive and require intravenous infusion or subcutaneous injection, and health-care providers must monitor their administration closely.Although molnupiravir—which is named after the Norse god Thor’s hammer, Mjollnir—was being tested for the treatment of the Ebola virus, researchers had not settled upon a purpose for the drug before SARS-CoV-2 arrived on the scene. Early studies of molnupiravir showed that its recipients cleared the coronavirus more rapidly than recipients of a placebo did. The drug did not help patients who were already hospitalized, but in outpatients with mild to moderate disease who had a high vulnerability to severe disease, it reduced the risk of hospitalization or death by 30 percent if given within five days of developing symptoms. The drug proved so beneficial that the clinical study was called off early. Merck applied for emergency-use authorization, and the FDA is expected to review the drug this week. Merck has promised to share its technology with the Medicines Patent Pool (MPP), which will allow for more affordable global access to molnupiravir.Paxlovid, a formula developed largely from scratch for the current pandemic, is actually an RNA-virus protease inhibitor called PF-07321332 “boosted” with another drug called ritonavir. It too was the subject of a clinical trial that was stopped early because the treatment looked so effective. Outpatients who had both COVID-19 and medical conditions that put them at high risk of severe illness were 89 percent less likely to be hospitalized if they received Paxlovid twice daily for five days than if they got a placebo. The FDA will likely review this important therapeutic before the end of the year. The U.S. government has bought millions of courses of molnupiravir and Paxlovid for Americans in anticipation of the authorization of both. Moreover, Pfizer has promised to accelerate worldwide access to Paxlovid through an agreement with MPP.[Read: A much-hyped COVID-19 drug is almost identical to a black-market cat cure]The importance of these two highly anticipated outpatient antivirals for COVID-19 cannot be overstated. Both medications were studied in unvaccinated individuals, of which the U.S. and other countries around the world have many. For the vaccinated, “breakthrough” infections are generally mild, but they can lead to time out of work and require cutting back contact with others. Not only should rapid treatment with one of these two antivirals shorten symptoms in breakthrough infections (as is the case with influenza), but bringing down the viral load quickly by inhibiting viral replication should limit transmission.Further study of the new COVID-19 drugs is under way for potential use in lower-risk individuals and as preventive medications. The development of HIV antivirals also led to the development of “post-exposure prophylaxis,” a strategy in which people who have come in contact with that virus take antivirals to avoid becoming HIV-positive. The new COVID drugs have at least the potential to provide a similar benefit. Moreover, the development of these two antivirals is spurring research on other COVID-19-specific antivirals. So despite the arrival of Omicron, we still have grounds for optimism. Last year ended with the authorization of highly effective COVID-19 vaccines, and 2021 should end with the availability of highly effective, targeted COVID-19 treatments that will help the world live with COVID-19.
theatlantic.com
Opinion: End of an era? Questions mount for Pete Carroll, Russell Wilson amid Seahawks' struggles
The Seahawks don't have much hope remaining entering Monday night's game, and a lost season will spark questions for Russell Wilson and Pete Carroll.       
usatoday.com
NFL Week 12 winners and losers: Bill Belichick has Patriots rolling. Wounded Titans are in a freefall.
Behind rookie QB Mac Jones and a strong defense, the Patriots look dangerous. The win-now Rams, meanwhile, have issues to resolve.       
usatoday.com
"Good reason to be worried" as Omicron COVID variant spreads fast
But South Africa, after quickly detecting and reporting the strain, feels punished for its sound science as other nations slam the door shut.
cbsnews.com
'I Made a $4million Chess Set'
The set has 20,000 diamonds of different sizes across the 32 pieces; that's a lot of stone setting. I had to assemble a small team of highly skilled setters to help me put the diamonds in absolutely perfectly.
newsweek.com
Dems’ dicey decision: Punish Boebert or not?
And the Senate stares down a December pileup.
politico.com
Commentary: What virtual reality and artificial intelligence will mean for sex, love and intimacy
Enormous advances in technology could transform the world that began with chatbots and sex robots.
latimes.com
Video of Nancy Mace's Differing Vaccine Remarks on Fox News and CNN Goes Viral
Nancy Mace was criticised by a Johns Hopkins surgeon Joseph Sakran and dubbed "reckless."
newsweek.com
Cristiano Ronaldo benching for Manchester United causes fierce debate between pundits
Cristiano Ronaldo's benching in Manchester United's 1-1 draw against Chelsea on Sunday prompted a fierce debate between leading pundits Jamie Carragher and Roy Keane.
edition.cnn.com
Op-Ed: Payouts for whistleblowers aren't enough. Workers need to know they can make a difference
That's the only reliable way to marshal insiders as corporate watchdogs.
1 h
latimes.com
Roe v. Wade Being Overturned Will Harm Black Women the Most
Mississippi has asked the Supreme Court to overturn the landmark 1973 ruling in a case seeking to revive a 15-week abortion ban.
1 h
newsweek.com
Biden's agenda brings warring conservative factions together in quest to flip House
The US Chamber of Commerce last year endorsed 23 vulnerable freshman House Democrats -- the most in at least a decade -- and enraged House GOP Leader Kevin McCarthy and other top Republicans who accused their long-time big business allies of heresy.
1 h
edition.cnn.com
Jussie Smollett taking the stand could be a double-edged sword in alleged hate crime hoax case, attorneys say
The trial of Jussie Smollett kicks off on Monday, nearly three years after the 39-year-old actor allegedly orchestrated a hate crime against himself, telling police that two White men in MAGA hats attacked him, shouted slurs, and put a noose around his neck.
1 h
foxnews.com
Jussie Smollett taking the stand could be a double-edged sword in alleged hate crime hoax case, attorneys say
The trial of Jussie Smollett kicks off on Monday, nearly three years after the 39-year-old actor allegedly orchestrated a hate crime against himself, telling police that two White men in MAGA hats attacked him, shouted slurs, and put a noose around his neck.
1 h
foxnews.com
Big pharma isn't the only powerful player in the prescription drug pricing fight
A well-funded counteroffensive is being waged by powerful collection of patient groups, health insurers, hospitals, other health-care interests and AARP. And they've arguably won the first round.
1 h
washingtonpost.com
What to know from NFL Week 12: The Rams are spiraling, and the 49ers are surging
Plus, Ben Roethlisberger and Cam Newton had rough outings, the Cowboys caught a break, and the Dolphins showed they aren't dead yet.
1 h
washingtonpost.com
Finding someone to handle your end-of-life, after-death affairs when you have no friends or relatives
REAL ESTATE MATTERS | Without friends or family, you’ll need to find support. And you may need two different kinds of help, because you could potentially have a situation where you need one type of assistance while you are alive and another after you have died.
1 h
washingtonpost.com
Editorial: Please Supreme Court, do not take abortion rights away from any women, anywhere
The Supreme Court is hearing a case asking it to overturn Roe vs. Wade, but it should reject it and continue to protect access to abortion.
1 h
latimes.com
Pa. commissioners called LGBTQ gathering a ‘hate group’ and denied funds to library where it was to meet. So citizens stepped in.
Fundraising campaigns have brought in $40,000 for the small library, far exceeding the $3,000 that was rejected by the local government.
1 h
washingtonpost.com
Countries Close Borders as More Omicron Cases Emerge
Scotland said it had found six cases of the new variant and that contact tracing was underway. Japan barred all foreign travelers, and Australia delayed reopening its borders for two weeks.
1 h
nytimes.com
‘Insecure’ and the defiant come-up of Issa Rae
"Insecure's" Issa Rae has come a long way since "The Misadventures of Awkward Black Girl."
1 h
washingtonpost.com
Letters to the Editor: Critical race theory's loudmouth critics are making teachers' jobs impossible
Educators and administrators develop curriculum carefully. Demands to ban critical race theory from the classroom circumvent that process
1 h
latimes.com